CR20110238A - Anticuerpos muc1* - Google Patents

Anticuerpos muc1*

Info

Publication number
CR20110238A
CR20110238A CR20110238A CR20110238A CR20110238A CR 20110238 A CR20110238 A CR 20110238A CR 20110238 A CR20110238 A CR 20110238A CR 20110238 A CR20110238 A CR 20110238A CR 20110238 A CR20110238 A CR 20110238A
Authority
CR
Costa Rica
Prior art keywords
muc1 antibodies
muc1
antibodies
monotional
antibody
Prior art date
Application number
CR20110238A
Other languages
English (en)
Inventor
Cynthia Bamdad
Mahanta Sanjeev
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of CR20110238A publication Critical patent/CR20110238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Abstract

La presente describe un anticuerpo monocional a MUC1*
CR20110238A 2008-10-06 2011-05-06 Anticuerpos muc1* CR20110238A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06

Publications (1)

Publication Number Publication Date
CR20110238A true CR20110238A (es) 2012-05-29

Family

ID=42101177

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110238A CR20110238A (es) 2008-10-06 2011-05-06 Anticuerpos muc1*

Country Status (8)

Country Link
US (4) US20170204191A1 (es)
EP (3) EP2337801A4 (es)
JP (3) JP2012504961A (es)
KR (1) KR101455447B1 (es)
CN (1) CN102239182B (es)
CR (1) CR20110238A (es)
IL (1) IL212175B (es)
WO (1) WO2010042562A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2337801A4 (en) 2008-10-06 2012-07-25 Minerva Biotechnologies Corp MUC1 ANTIBODIES *
KR20140101876A (ko) 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
KR101853418B1 (ko) * 2010-06-16 2018-05-02 미네르바 바이오테크놀로지 코포레이션 암 세포의 역분화
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
WO2012126013A2 (en) * 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
EP2872636A4 (en) * 2012-07-13 2016-08-17 Minerva Biotechnologies Corp METHOD FOR INDUCING A MINIMUM CELL TREATMENT CONDITION
EP2885000A4 (en) * 2012-08-14 2015-12-23 Minerva Biotechnologies Corp STEM CELL IMPROVING THERAPEUTICS
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CA2898239A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
JP6908381B2 (ja) * 2014-01-29 2021-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
IL250902B (en) * 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
JP2017536091A (ja) 2014-10-02 2017-12-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 多価メディトープ、メディトープ結合性抗体およびそれらの使用
JP6574257B2 (ja) * 2014-10-07 2019-09-11 アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ 新規の抗Ｎｏｄａｌ抗体及びその使用方法
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
WO2017185662A1 (zh) * 2016-04-29 2017-11-02 深圳市中联生物科技开发有限公司 多特异性结合偶联物、相关的药物组合物及应用
KR20180134837A (ko) * 2015-12-09 2018-12-19 코버스 파마슈티칼스, 인크. 인간화된 항-cd73 항체
JP2020514304A (ja) * 2017-01-27 2020-05-21 グリコトープ ゲーエムベーハー 抗ＭＵＣ１抗体およびＥｒｂＢ阻害剤を用いた抗がん処置
US10851164B2 (en) * 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
WO2020146902A2 (en) * 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
KR20230028796A (ko) * 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
IL299903A (en) * 2020-07-16 2023-03-01 Dana Farber Cancer Inst Inc Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD)
US11970546B2 (en) 2020-07-31 2024-04-30 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) * 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
DE69941031D1 (de) 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2002000255A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre le cancer
WO2002022685A2 (en) 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US7700715B2 (en) * 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
EP1578345A2 (en) 2001-03-29 2005-09-28 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) * 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
EP2116248A1 (en) 2001-09-05 2009-11-11 Minerva Biotechnologies Corporation Compositions and Methods of Treatment of Cancer
CN100360567C (zh) * 2002-03-01 2008-01-09 免疫医疗公司 Rs7抗体
CA2482596A1 (en) 2002-04-22 2003-10-30 Dyax Corp. Antibodies specific for mucin polypeptide
WO2003106495A2 (en) * 2002-06-14 2003-12-24 Immunomedics, Inc. MONOCLONAL ANTIBODY hPAM4
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
DE602005018325D1 (de) * 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
CN101035810B (zh) * 2004-10-04 2011-04-06 健泰科生物技术公司 肝细胞生长因子激活剂的调控物
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
WO2008070171A2 (en) 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Method for identifying and manipulating cells
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
EP2337801A4 (en) 2008-10-06 2012-07-25 Minerva Biotechnologies Corp MUC1 ANTIBODIES *
EP2885000A4 (en) * 2012-08-14 2015-12-23 Minerva Biotechnologies Corp STEM CELL IMPROVING THERAPEUTICS

Also Published As

Publication number Publication date
US20230295340A1 (en) 2023-09-21
KR20110067153A (ko) 2011-06-21
US20170204191A1 (en) 2017-07-20
CN102239182A (zh) 2011-11-09
IL212175A0 (en) 2011-06-30
IL212175B (en) 2019-08-29
JP2012504961A (ja) 2012-03-01
EP2337801A4 (en) 2012-07-25
KR101455447B1 (ko) 2014-10-27
EP4083072A1 (en) 2022-11-02
EP3130607B1 (en) 2024-04-17
US11560435B2 (en) 2023-01-24
US20180222998A1 (en) 2018-08-09
US10421819B2 (en) 2019-09-24
EP3130607A3 (en) 2017-06-28
JP6230983B2 (ja) 2017-11-15
JP2017176174A (ja) 2017-10-05
CN102239182B (zh) 2014-07-09
JP2015071614A (ja) 2015-04-16
EP2337801A2 (en) 2011-06-29
JP6392923B2 (ja) 2018-09-19
WO2010042562A3 (en) 2010-09-30
WO2010042562A2 (en) 2010-04-15
US20200239594A1 (en) 2020-07-30
EP3130607A2 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
CR20110238A (es) Anticuerpos muc1*
CY2019040I1 (el) Aνti-il-23 αντισωματα
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
SMT201700083B (it) Anticorpi monoclonali
BRPI0923359A2 (pt) Anticorpos anti-igf
CL2014000126A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BR112012002226A2 (pt) anticorpos muc1.
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI0819165A2 (pt) Anticorpos anti-vegf
ECSP14005992A (es) Proteinas que pueden unirse a la il-1
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados
BRPI1010297A2 (pt) anticorpos biespecíficos trivalentes.
DK2262836T3 (da) Antistof mod CSF-1R
BRPI0809677A2 (pt) Anticorpos anti-ige
DK2443154T3 (da) Bispecifikke antigenbindingsproteiner
CR20170001A (es) Anticuerpos anti factor d humanizados
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
BRPI0918648A2 (pt) anticorpos multiespecíficos
SG10201601279SA (en) Monoclonal Antibody STRO-4
BR112012017051A2 (pt) método para diminuir a imunogenicidade
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet